Overview
- Celltrion committed 4 trillion won to expand domestic manufacturing, including new plants in Songdo and Yesan and a prefilled syringe facility in Ochang.
- The company filed to invest up to 700 billion won to upgrade the Branchburg, New Jersey site, adding three 11,000-liter bioreactors first and three more later to reach 66,000 liters over five years.
- Regulatory reviews in the U.S. and Ireland have been completed, and Celltrion aims to close the Eli Lilly Branchburg acquisition by year-end after agreeing to the deal in September.
- Total U.S. site spending is projected at about 1.4 trillion won, covering the $330 million purchase and phased upgrades to establish a one-stop U.S. production-to-commercialization chain.
- Celltrion targets 18 biosimilars by 2030 and 41 by 2038, guides for over 30% quarter-on-quarter sales growth in Q4, and reported 1.03 trillion won in Q3 sales.